Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.71 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | ATR | Q13535 | 4/20 | 0.45 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619144 | 0.93 | ALB (0.61) | ALBCHEK2FLT3SCD | |
| SCHEMBL16630755 | 0.83 | ALB (1.00) | ALBCHEK2ATRHTR2BSCD | |
| SCHEMBL16619766 | 0.79 | ALB (0.67) | ALBCHEK2 | |
| SCHEMBL16619335 | 0.78 | ALB (0.62) | ALBATRFLT3 | |
| SCHEMBL16630761 | 0.77 | ALB (0.86) | ALBCHEK2SCD | |
| SCHEMBL16619475 | 0.75 | HDAC6 (0.58) | ALBCHEK2FLT3 | |
| SCHEMBL16619924 | 0.74 | ALB (0.61) | ALBCHEK2ATRHTR2B | |
| SCHEMBL16619938 | 0.73 | ALB (0.58) | ALBCHEK2 | |
| SCHEMBL16630759 | 0.72 | ALB (0.78) | ALBCHEK2SCD | |
| SCHEMBL20034144 | 0.70 | ALB (0.63) | ALBCHEK2ATRHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809558-B2 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-3052483-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| WO-2015049651-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221962-A1 | COMPOUNDS FOR AFFINITY CHROMATOGRAPHY AND FOR EXTENDING THE HALF-LIFE OF A THERAPEUTIC AGENT | ALB, HDGF, VEGFA | ALB 1/4885CHEK2 4260/4885ATR 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.